10 November 2016
Moscow, November 10, 2016 – Russian pharmaceutical company NovaMedica launches R&D laboratories as part of its Technology Center project for the development and pilot production of innovative drugs. The facilities are designed to address the most challenging scientific tasks based on the state-of-the-art platforms incorporating nanotechnologies. The project investment totals $15m.
“The first R&D projects are due to start in NovaMedica’s Technology Center laboratories in December 2016. By 2022, we are planning to take about 20% of the contract R&D market in the Russian pharmaceutical industry,” commented Alexander Kuzin, Managing Director of NovaMedica. “Our R&D hub will be a rare example of synergy between scientific tasks and their practical application in Russia.”
“The plan is to promote cooperation with the leading American and European R&D centers,” added Mikhail Getman, Vice-President, Pharmaceutical Operations, head of the company’s R&D division. “The Technology Center will become a bridge for bringing in the new tech-knowledge and pharmaceutical developments, spreading them to various manufacturing facilities across the country and, in time, exporting. One of our goals is not only to take a considerable share of the dosage form development market in Russia, but also to transform the market itself by creating the new segment of state-of-the-art solutions for innovative drug development.”
According to Olga Shpichko, Managing Director for Investment Operations of RUSNANO Management Company, NovaMedica is already working on a number of quite interesting innovative drugs and the R&D facility will fast track the development and marketing of products essential for Russian patients.
At the same time, the company is building 9 pilot production areas with the total capacity of up to 80 million doses (tablets/capsules) per year and recruiting analysts, process and production personnel. The Technology Center with the total floor area of about 1800 m2 will be fully launched in the first quarter of 2017. Further steps will include commissioning, validation and licensing.
NovaMedica Innotech is NovaMedica’s R&D division focusing on the development of innovative drug forms allowing API bioavailability modifications and new combinations of earlier incompatible substances. NovaMedica started the Technology Center construction project at the Technopolis Moscow site in December 2015.
ROSNANO was founded as a joint stock company in March 2011, through reorganization of the state-owned Russian Corporation of Nanotechnologies. RUSNANO, JSC is instrumental in realizing the Government policies for nanoindustry growth, investing in financially effective high-tech projects ensuring the development of new manufacturing in the Russian Federation. Its primary investment focus is in electronics, optoelectronics and telecommunications, healthcare and biotechnology, metallurgy and metalwork, energy, mechanical engineering and instrument making, construction and industrial materials, chemicals and petrochemicals. The Government of the Russian Federation owns 100% of RUSNANO shares. RUSNANO investments made possible 73 plants and R&D centers across 28 regions of the Russian Federation. RUSNANO assets are managed by a limited liability company established in December 2013 – RUSNANO Management Company. Anatoly Chubais is the Chairman of its Executive Board. Development of the nanotech industry infrastructure and educational programs is driven by the Fund for Infrastructure and Educational Programs also founded through the reorganization of the Russian Corporation of Nanotechnologies. More information is available at www.rusnano.com.
NovaMedica is a modern Russian pharmaceutical company established in 2012 by the leading U.S. venture capital firm Domain Associates, LLC and RUSNANO, JSC. NovaMedica has well- developed infrastructure for the promotion and sales of pharmaceutical products. Today, the company promotes 25 ophthalmology and gastroenterology products in Russia. NovaMedica's strategy is focused on the search, registration and localization of innovative pharmaceutical products and technologies, as well as the development of the company’s own R&D projects. The company is currently building a Technology Center in Moscow that will include R&D laboratories and state-of-the-art pilot production facilities previously unavailable in the Russian pharmaceutical industry. In July 2016, NovaMedica paertnered with Pfizer aiming to create a high-tech pharmaceutical GMP-compliant manufacturing facility in Kaluga Region. NovaMedica’s R&D division is one of Skolkovo residents. Learn more about NovaMedica at www.novamedica.com follow us on Facebook and LinkedIn.Print
20 February 2018
20 February 2018
20 February 2018
19 February 2018